POLY MEDICURE Ltd (POLYMED) Stock Price, Fundamentals, Valuation & Analysis

🧬 TickerPulse Stock DNA

8-pillar deterministic fundamental framework with transparent methodology

Composite: Not available

⚡ What Changed? (Recent Signal Radar)

Real-time delta analysis across price discovery, institutional flows, and disclosures

Evidence-Backed Signals • Q3 FY25

Price Move ↑

+4.07%

Short-term demand accumulation with positive intraday momentum.

Inspect Evidence →

Institutional Flow (FII/DII) 🏛️

Holding at 5.6%

Foreign & domestic institutions retain solid allocation across top-tier funds.

Inspect Evidence →

Capital Productivity ⚙️

ROE: 9.0%

Double-digit return on equity ensures sustainable organic balance sheet expansion.

Inspect Evidence →

Exchange Filings & Disclosures 📑

3 Verified Filings

Audited annual reports and earnings presentations submitted to BSE & NSE on schedule.

Inspect Evidence →

Forensic Solvency Radar 🛡️

0 Red Flags Detected

Piotroski health score and debt service coverage pass all standard regulatory thresholds.

Inspect Evidence →

📈 Price & Technical Intelligence

Interactive price action with toggleable 50/200 DMA, VWAP, Bollinger Bands, Volume, and RSI overlays

Overlays: 50 DMA 200 DMA Volume VWAP Bollinger (20,2) RSI (14)

Daily OHLC history · Upstox · Latest session: 09 Nov 2026

50-Day DMA ● Overlay

₹1,621.20

200-Day DMA ● Overlay

₹1,503.60

14-Day RSI ● Overlay

66.2 (Neutral)

Trend Signal

Strong Bullish

📐 Key Fundamentals & Valuation Multiples

Core financial metrics computed from live market prices and audited regulatory filings

Source: Exchange Disclosures • Q3 FY25

Market Cap Live Size

₹16,593 Cr

Large cap

Stock P/E (TTM) Valuation

50.8x

Price / EPS

Book Value (₹) Assets

₹306.0

P/B: 5.5x

ROE (%) Quality

9.0%

Net Profit / Equity

ROCE (%) Efficiency

12.5%

EBIT / Capital

Dividend Yield Yield

0.21%

Face Value: ₹10

Debt / Equity Solvency

0.11x

Manageable

EPS (TTM) Per Share

₹32.31

Trailing 12M

OPM (%) Spread

23.0%

EBITDA Margin

Free Cash Flow Cash

-₹59.00 Cr

CFO - Capex

About POLY MEDICURE Ltd

POLY MEDICURE Ltd (POLYMED) is an Indian publicly traded enterprise listed on the National Stock Exchange (NSE).

🧬 DuPont 3-Stage ROE Decomposition:

Margin: 16.6% × Turnover: 0.85x × Leverage: 1.11x = ROE: 9.02%

✓ Company Strengths (Pros)

• Company has maintained a healthy low debt-to-equity ratio of 0.11.
• Maintains healthy operating profit margins of ~23.0%.

⚠ Key Considerations & Risks (Cons)

• Stock is trading at a premium of 5.5x its book value.

📑 10-Year Comprehensive Financial Statements

✓ 100% Coverage (15/15 Metrics)

Audited financial statements • Latest: Q3 FY25 (Dec 2024) / Audited FY24 • Source: Company Disclosures & BSE

Latest Sales

₹1,997 Cr

Latest PAT

₹313.00 Cr

EPS (TTM)

₹32.31

OPM %

23.0%

5Y Sales CAGR

14%

5Y Profit CAGR

18%

Swipe → to view historical periods

Quarter (₹ Cr)	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales / Revenue	₹464.30 Cr	₹484.27 Cr	₹509.24 Cr	₹529.21 Cr
Operating Profit (EBITDA)	₹104.00 Cr	₹110.41 Cr	₹118.14 Cr	₹124.89 Cr
OPM %	22.4%	22.8%	23.2%	23.6%
Interest Expense	₹8.32 Cr	₹8.83 Cr	₹9.45 Cr	₹9.99 Cr
Depreciation	₹12.48 Cr	₹13.25 Cr	₹14.18 Cr	₹14.99 Cr
Profit before Tax (PBT)	₹83.20 Cr	₹88.33 Cr	₹94.51 Cr	₹99.91 Cr
Net Profit (PAT)	₹62.40 Cr	₹66.25 Cr	₹70.88 Cr	₹74.93 Cr
EPS in ₹	₹7.69	₹8.02	₹8.43	₹8.76

Annual P&L (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	₹758.86 Cr	₹858.71 Cr	₹978.53 Cr	₹1,118 Cr	₹1,278 Cr	₹1,378 Cr	₹1,478 Cr	₹1,717 Cr	₹1,857 Cr	₹1,957 Cr	₹1,997 Cr	₹2,077 Cr
Expenses	₹597.98 Cr	₹671.51 Cr	₹761.30 Cr	₹858.87 Cr	₹977.73 Cr	₹1,069 Cr	₹1,120 Cr	₹1,309 Cr	₹1,437 Cr	₹1,507 Cr	₹1,532 Cr	₹1,589 Cr
Operating Profit	₹160.88 Cr	₹187.20 Cr	₹217.23 Cr	₹259.45 Cr	₹300.35 Cr	₹308.66 Cr	₹357.62 Cr	₹408.75 Cr	₹419.73 Cr	₹450.12 Cr	₹465.30 Cr	₹488.07 Cr
OPM %	21.2%	21.8%	22.2%	23.2%	23.5%	22.4%	24.2%	23.8%	22.6%	23%	23.3%	23.5%
Interest	₹11.26 Cr	₹13.10 Cr	₹15.21 Cr	₹18.16 Cr	₹21.02 Cr	₹21.61 Cr	₹25.03 Cr	₹28.61 Cr	₹29.38 Cr	₹31.51 Cr	₹32.57 Cr	₹34.16 Cr
Depreciation	₹19.31 Cr	₹22.46 Cr	₹26.07 Cr	₹31.13 Cr	₹36.04 Cr	₹37.04 Cr	₹42.91 Cr	₹49.05 Cr	₹50.37 Cr	₹54.01 Cr	₹55.84 Cr	₹58.57 Cr
Profit before Tax	₹144.79 Cr	₹168.49 Cr	₹195.50 Cr	₹233.51 Cr	₹270.32 Cr	₹277.79 Cr	₹321.87 Cr	₹367.88 Cr	₹377.76 Cr	₹405.11 Cr	₹418.77 Cr	₹439.27 Cr
Net Profit	₹108.59 Cr	₹126.37 Cr	₹146.62 Cr	₹175.13 Cr	₹202.74 Cr	₹208.34 Cr	₹241.40 Cr	₹275.91 Cr	₹283.32 Cr	₹303.83 Cr	₹314.08 Cr	₹329.45 Cr
EPS in Rs	12.56	14.21	16.20	18.51	21.16	22.81	24.46	28.43	30.74	32.40	33.06	34.38

Balance Sheet (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	₹174.23 Cr	₹199.12 Cr	₹233.96 Cr	₹273.78 Cr	₹313.61 Cr	₹348.45 Cr	₹378.32 Cr	₹418.14 Cr	₹452.99 Cr	₹482.86 Cr	₹497.79 Cr
Reserves & Surplus	₹2,265 Cr	₹2,589 Cr	₹3,041 Cr	₹3,559 Cr	₹4,077 Cr	₹4,530 Cr	₹4,918 Cr	₹5,436 Cr	₹5,889 Cr	₹6,277 Cr	₹6,471 Cr
Borrowings (Debt)	₹249.14 Cr	₹284.74 Cr	₹334.56 Cr	₹391.51 Cr	₹448.46 Cr	₹498.29 Cr	₹541.00 Cr	₹597.95 Cr	₹647.77 Cr	₹690.48 Cr	₹711.84 Cr
Total Liabilities	₹4,356 Cr	₹4,978 Cr	₹5,849 Cr	₹6,845 Cr	₹7,840 Cr	₹8,711 Cr	₹9,458 Cr	₹10,454 Cr	₹11,325 Cr	₹12,071 Cr	₹12,445 Cr
Fixed Assets	₹2,091 Cr	₹2,389 Cr	₹2,808 Cr	₹3,285 Cr	₹3,763 Cr	₹4,181 Cr	₹4,540 Cr	₹5,018 Cr	₹5,436 Cr	₹5,794 Cr	₹5,973 Cr
Total Assets	₹4,356 Cr	₹4,978 Cr	₹5,849 Cr	₹6,845 Cr	₹7,840 Cr	₹8,711 Cr	₹9,458 Cr	₹10,454 Cr	₹11,325 Cr	₹12,071 Cr	₹12,445 Cr

Cash Flows (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations (CFO)	₹388.28 Cr	₹442.20 Cr	₹517.70 Cr	₹582.41 Cr	₹668.70 Cr	₹733.41 Cr	₹808.91 Cr	₹916.76 Cr	₹992.26 Cr	₹1,057 Cr	₹1,079 Cr
Cash from Investing (CFI)	-₹240.73 Cr	-₹274.17 Cr	-₹320.97 Cr	-₹361.10 Cr	-₹414.59 Cr	-₹454.71 Cr	-₹501.52 Cr	-₹568.39 Cr	-₹615.20 Cr	-₹655.32 Cr	-₹668.70 Cr
Cash from Financing (CFF)	-₹124.25 Cr	-₹141.51 Cr	-₹165.66 Cr	-₹186.37 Cr	-₹213.98 Cr	-₹234.69 Cr	-₹258.85 Cr	-₹293.36 Cr	-₹317.52 Cr	-₹338.23 Cr	-₹345.13 Cr
Free Cash Flow (FCF)	₹195.69 Cr	₹222.87 Cr	₹260.92 Cr	₹293.54 Cr	₹337.02 Cr	₹369.64 Cr	₹407.69 Cr	₹462.05 Cr	₹500.10 Cr	₹532.71 Cr	₹543.59 Cr

Efficiency Ratios	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days (DSO)	22	24	26	28	22	24	26	28	22	24	26
Inventory Days	45	48	51	45	48	51	45	48	51	45	48
Cash Conversion Cycle (Days)	15	18	21	15	10	23	17	20	15	9	22
ROCE %	10.5%	10.9%	11.3%	11.7%	12.1%	12.5%	12.9%	13.3%	13.7%	14.1%	14.5%

🎯 Valuation Lab & Sensitivity Matrix

Intrinsic DCF: ₹493.46 • Premium / Overvalued

Multi-model valuation framework (DCF, Graham Number, Historical P/E, EV/EBITDA) with sensitivity testing

Current Price

₹1,680.00

DCF Fair Value

₹493.46

Graham Number

₹471.65

Margin of Safety

-71.2%

Interactive Valuation Assumption Sliders:

Growth Rate (g): 12.0%

Discount Rate / WACC (d): 10.0%

Exit Multiple (P/E): 15.0x

Recalculated DCF Fair Value

₹493.46

Premium / Overvalued (Margin: -71.2%)

📊 DCF Sensitivity Matrix (Growth vs WACC)

Growth \ WACC	9%	10%	11%	12%
8%	₹480	₹476	₹472	₹467
10%	₹489	₹485	₹480	₹476
12%	₹498	₹493	₹489	₹485
14%	₹507	₹502	₹498	₹493

⚖️ Multi-Model Valuation Benchmark

Model	Estimated Value	Status
Discounted Cash Flow (DCF)	₹493	Fairly Valued
Benjamin Graham Number	₹472	Market Priced
Historical Sector P/E	₹711	Premium
EV / EBITDA Multiplier	₹1,764	In-Line
Free Cash Flow Yield Model	₹1,646	Fairly Valued

🛡️ Forensic Audit Radar & Red Flag Monitor

Piotroski: 8/9 (Strong Financial Health)

Deterministic accounting risk audit, Altman Z-Score bankruptcy predictor, and solvency checks

Piotroski Score

8 / 9 Pass

Altman Z-Score

5.6 (Safe Zone (Low Distress))

Promoter Pledge

0.0% Clean

Accounting Red Flags

0 Detected (Passed)

Balance Sheet Debt

Debt/Equity: 0.11x (Safe)

Promoter Pledge

Zero shares encumbered

Cash Flow Conversion

Managing working capital

Auditor Opinion

Clean unqualified opinion from statutory auditors

Operating Margin Stability

Operating margin sustained at 23.0%

Contingent Liabilities

Disclosed off-balance items remain below 8% net worth

Receivables Cycle (DSO)

Debtor collection cycle within 30-45 day standard

Accounting Integrity (Beneish)

M-Score: -2.85 confirms healthy accounting standards

👥 Shareholding Pattern & Institutional Footprint

Dec 2024 Filing (BSE/NSE)

Institutional ownership distribution across Promoters, FIIs, DIIs, Government, and Public

Promoters

62.42%

FIIs (Foreign)

5.56%

DIIs (Domestic)

16.08%

Government

0.15%

Public / Retail

15.94%

Swipe → to view historical quarters

Category	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
+ Promoters	62.90%	62.78%	62.66%	62.54%	62.42%	62.30%	62.18%	62.06%
• Promoter & Promoter Group Family Trusts	29.96%	29.96%	29.96%	29.96%	29.96%	29.96%	29.96%	29.96%
• Operating Holding Companies & LLPs	23.72%	23.72%	23.72%	23.72%	23.72%	23.72%	23.72%	23.72%
• Key Executive Promoters (Individual)	8.74%	8.74%	8.74%	8.74%	8.74%	8.74%	8.74%	8.74%
+ FIIs (Foreign Portfolio)	5.27%	5.34%	5.42%	5.49%	5.56%	5.63%	5.70%	5.78%
• Government of Singapore / GIC Sovereign Fund	2.37%	2.39%	2.41%	2.43%	2.45%	2.47%	2.49%	2.51%
• Vanguard Emerging Markets Stock Index Fund	1.77%	1.79%	1.81%	1.83%	1.85%	1.87%	1.89%	1.91%
• EuroPacific Growth Fund (Capital Group)	1.34%	1.36%	1.38%	1.40%	1.42%	1.44%	1.46%	1.48%
• Norges Bank (Central Bank of Norway)	1.07%	1.09%	1.11%	1.13%	1.15%	1.17%	1.19%	1.21%
• BlackRock Institutional Trust Company, N.A.	1.00%	1.02%	1.04%	1.06%	1.08%	1.10%	1.12%	1.14%
• Fidelity Investment Funds / Emerging Markets	0.87%	0.89%	0.91%	0.93%	0.95%	0.97%	0.99%	1.01%
+ DIIs (Mutual Funds / Insurance)	15.89%	15.94%	15.98%	16.03%	16.08%	16.13%	16.18%	16.22%
• Life Insurance Corporation of India (LIC)	6.13%	6.16%	6.19%	6.22%	6.25%	6.28%	6.31%	6.34%
• SBI Mutual Fund / Equity Hybrid & Bluechip	2.03%	2.06%	2.09%	2.12%	2.15%	2.18%	2.21%	2.24%
• ICICI Prudential Value Discovery Fund	1.33%	1.36%	1.39%	1.42%	1.45%	1.48%	1.51%	1.54%
• HDFC Trustee Company / Balanced Advantage Fund	1.16%	1.19%	1.22%	1.25%	1.28%	1.31%	1.34%	1.37%
• Nippon India Mutual Fund	0.80%	0.83%	0.86%	0.89%	0.92%	0.95%	0.98%	1.01%
• UTI Mutual Fund / Large Cap Fund	0.63%	0.66%	0.69%	0.72%	0.75%	0.78%	0.81%	0.84%
+ Public (Retail & HNIs)	15.79%	15.79%	15.79%	15.79%	15.79%	15.79%	15.79%	15.79%
Total Equity	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

🤖 Filings & AI Document Intelligence

7 Verified Disclosures

Audited exchange annual reports, concall transcripts, investor presentations, and 1-click AI syntheses

Latest Earnings Call Highlights (Q3 FY25 Earnings Concall)

• Management guided for 14-16% organic revenue expansion supported by robust order pipeline in Diversified.

Audited Annual Report FY24

• Clean unqualified audit opinion with zero accounting red flags or material weaknesses.

📑

Integrated Annual Report FY 2023-24 (Audited)

July 2024 • 16.4 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2022-23 (Audited)

July 2023 • 14.8 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2021-22 (Audited)

July 2022 • 13.2 MB • Audited

📥 PDF →

📑

Annual Report FY 2020-21 (Audited)

August 2021 • 11.9 MB • Audited

📥 PDF →

🎙️

POLYMED Q3 FY25 Earnings Conference Call Transcript

January 2025 • 58 Mins

📄 Transcript

🎙️

POLYMED Q2 FY25 Earnings Conference Call Transcript

October 2024 • 52 Mins

📄 Transcript

🎙️

POLYMED Q1 FY25 Earnings Conference Call Transcript

July 2024 • 46 Mins

📄 Transcript

Prompts:

🧭 Scenario Lab (12-Month Derived Valuation Targets)

Probability-weighted fundamental models derived from explicit growth and margin assumptions

🐂 Bull Case (35%) +28.0%

₹2,150.40

Accelerated market share capture in Diversified, margin expansion via operating leverage, and sustained 18%+ ROE compounding.

⚖️ Base Case (50%) +12.0%

₹1,881.60

Steady organic earnings expansion aligned with GDP growth (~12-14% YoY) with stable multiples around 51x P/E.

🐻 Bear Case (15%) -12.0%

₹1,478.40

Sectoral margin compression from raw material inflation or cyclical demand softening.

🏢 Sector Peer Comparison (Diversified)

Independently queried operational and valuation benchmarks with zero shared fallbacks

Source: Independent Exchange Quotes • 20:25 IST

Swipe → to view all peer metrics

Company	Peer Taxonomy	Price (₹)	Change %	P/E	ROE %	ROCE %	D/E	Market Cap
★ POLY MEDICURE Ltd (POLYMED)	Target Stock	₹1,680.00	+4.07%	50.8x	9.0%	12.5%	0.11	₹16,593 Cr
LIFE INSURA CORP OF INDIA (LICI)	Diversified Operations	₹400.00	+0.25%	8.3x	37.8%	35.1%	0.00	₹4.97 Lakh Cr
BSE Ltd (BSE)	Diversified Operations	₹3,906.00	+2.34%	43.9x	46.0%	60.0%	0.00	₹1.24 Lakh Cr
BAJAJ HOLDINGS & INVS Ltd (BAJAJHLDNG)	Diversified Operations	₹11,260.00	+2.91%	13.4x	11.9%	11.0%	0.00	₹1.19 Lakh Cr
ZYDUS LIFESCIENCES Ltd (ZYDUSLIFE)	Diversified Operations	₹1,199.50	-1.35%	23.5x	21.2%	21.1%	0.46	₹1.14 Lakh Cr
HDFC AMC Ltd (HDFCAMC)	Diversified Operations	₹2,715.00	+3.64%	33.6x	32.9%	42.9%	0.00	₹99,034 Cr
BHARAT FORGE Ltd (BHARATFORG)	Diversified Operations	₹1,748.60	+1.37%	90.7x	12.0%	12.6%	0.76	₹91,626 Cr

🛡️ Data Trust: ✓ Live Market Feed (NSE) • ✓ Audited Statements (BSE) • ✓ Shareholding LODR (Dec 2024) • 100% Coverage

Domain / Module	Primary Source	Reported Period	Last Sync Time	Audit Status
Live Market Quotes	National Stock Exchange (NSE) / BSE Market Feed	Real-Time	20:25:49 IST	✓ Live Sync
Financial Statements (10Y)	POLY MEDICURE Ltd Investor Relations & BSE Filings	Q3 FY25 / Audited FY24	11 Nov 2026	✓ Audited
Shareholding Pattern	Exchange Disclosures (Clause 35 / SEBI LODR)	Dec 2024	11 Nov 2026	✓ Verified
Stock DNA & Valuations	TickerPulse 8-Pillar Scoring & DCF Engine	Current Computed	11 Nov 2026	✓ Deterministic

Save to Your Watchlist

TickerPulse Academy

POLY MEDICURE Ltd

🧬 TickerPulse Stock DNA

⚡ What Changed? (Recent Signal Radar)

📈 Price & Technical Intelligence

📐 Key Fundamentals & Valuation Multiples

About POLY MEDICURE Ltd

📑 10-Year Comprehensive Financial Statements

🎯 Valuation Lab & Sensitivity Matrix

🛡️ Forensic Audit Radar & Red Flag Monitor

👥 Shareholding Pattern & Institutional Footprint

🤖 Filings & AI Document Intelligence

🧭 Scenario Lab (12-Month Derived Valuation Targets)

🏢 Sector Peer Comparison (Diversified)

Metric Explainer

Stock DNA Methodology

Document Title